» Articles » PMID: 36593072

Evaluation of the England Community Pharmacy Quality Scheme (2018-2019 and 2019-2020) in Reducing Harm from NSAIDs in Older Patients

Overview
Journal BMJ Open Qual
Specialty Health Services
Date 2023 Jan 2
PMID 36593072
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for their analgesic and anti-inflammatory action, but the gastrointestinal (GI) adverse effects are a known cause of preventable harm. A medication safety audit was incentivised for community pharmacies in England in 2 successive years as part of the Pharmacy Quality Scheme (PQS) to address GI safety of NSAIDs.

Aims: To evaluate community pharmacy's contributions to NSAID safety and determine any change between audit 1 (2018-2019) and audit 2 (2019-2020).

Method: Patients aged 65 years or over prescribed an NSAID were included in both audits. The audit tool assessed compliance with national standards relating to co-prescribed gastroprotection, referrals to the prescriber and patient advice on long-term NSAID use and effects, with responses submitted via an online portal. Descriptive analyses were performed to explore differences between the years and tested for significance using Χ tests. Qualitative data were analysed using an inductive thematic approach.

Key Findings: Data from 91 252 patients in audit 1 and 73 992 in audit 2 were analysed. More patients were prescribed gastroprotection in audit 2 (85.0%) than audit 1 (80.7%, p<0.001). More patients without gastroprotection in audit 2 had a current or recent referral (67.5%) than in audit 1 (58.8%, p<0.001). Verbal or other communications between pharmacists and patients about their NSAID medication were reported more frequently in audit 2 (76.0% vs 63.5%, p<0.001).

Conclusion: During two audits, community pharmacists in England reported referring more than 15 000 patients at risk of preventable harm from NSAIDs to prescribers for review. The audits demonstrated significant potential for year-on-year improvement in GI safety for a large cohort of older patients prescribed NSAIDs. This evaluation provides evidence of how the PQS can effectively address a specific aspect of medicines safety and the place of community pharmacy more broadly in improving medicines safety.

Citing Articles

An Evaluation of Oral Anticoagulant Safety Indicators by England's Community Pharmacies.

Parekh S, Xu L, Livingstone C Pharmacy (Basel). 2024; 12(5).

PMID: 39311125 PMC: 11417885. DOI: 10.3390/pharmacy12050134.


Estimating the economic effect of harm associated with high risk prescribing of oral non-steroidal anti-inflammatory drugs in England: population based cohort and economic modelling study.

Camacho E, Penner L, Taylor A, Guthrie B, Avery A, Ashcroft D BMJ. 2024; 386:e077880.

PMID: 39048136 PMC: 11268384. DOI: 10.1136/bmj-2023-077880.


Evaluation of the knowledge, practices, and attitudes of community pharmacists towards adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs): a cross-sectional study.

Barakat H, Aziz C, Abougalambou S J Pharm Policy Pract. 2023; 16(1):132.

PMID: 37915076 PMC: 10621222. DOI: 10.1186/s40545-023-00641-1.


Responding to Urinary Tract Infection Symptoms in England's Community Pharmacies.

Parekh S, Hand K, Xu L, Roberts V, Pursey F, Ashiru-Oredope D Antibiotics (Basel). 2023; 12(9).

PMID: 37760680 PMC: 10525945. DOI: 10.3390/antibiotics12091383.


The Use of the TARGET Antibiotic Checklist to Support Antimicrobial Stewardship in England's Community Pharmacies.

Parekh S, Hayes C, Loader J, Ashiru-Oredope D, Hand K, Hicks G Antibiotics (Basel). 2023; 12(4).

PMID: 37107009 PMC: 10135131. DOI: 10.3390/antibiotics12040647.

References
1.
Vane J, Bakhle Y, Botting R . Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998; 38:97-120. DOI: 10.1146/annurev.pharmtox.38.1.97. View

2.
Dalton S, Johansen C, Mellemkjaer L, Norgard B, Sorensen H, Olsen J . Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003; 163(1):59-64. DOI: 10.1001/archinte.163.1.59. View

3.
Rosenbloom C, Morley F, Ahmed I, Cox A . Oral non-steroidal anti-inflammatory drug use in recreational runners participating in Parkrun UK: Prevalence of use and awareness of risk. Int J Pharm Pract. 2020; 28(6):561-568. DOI: 10.1111/ijpp.12646. View

4.
Bhat S, Kroehl M, Yi W, Jaeger J, Thompson A, Lam H . Factors influencing the acceptance of referrals for clinical pharmacist managed disease states in primary care. J Am Pharm Assoc (2003). 2019; 59(3):336-342. PMC: 6756144. DOI: 10.1016/j.japh.2019.02.008. View

5.
Howard R, Avery A, Slavenburg S, Royal S, Pipe G, Lucassen P . Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2006; 63(2):136-47. PMC: 2000562. DOI: 10.1111/j.1365-2125.2006.02698.x. View